How to Avoid Delays in Your Early Phase Oncology Trial?

Webinar: How to Avoid Delays in Your Early Phase Oncology Trial?

Many things can go array in your early phase oncology trials, from protocol development, taking care of a safety profile, getting the ethics committee / regulatory authority’s approval, managing vendors, and much more. They all cost precious time and increase the overall costs.

Despite the challenges, the number of oncology clinical trials increases year after year as more treatment options seek to reach the market. At the same time, these studies are becoming progressively more complex, bringing new challenges. So, often a simple question arises: how to avoid these delays in early phase oncology studies?

Planning your next oncology study?

Let’s talk how we can team up to overcome common challenges and ensure smooth processes.

What we will talk about?

How to avoid the most common delays in early phase oncology trials:

  • Protocol development
  • Safety profile
  • Seeking approvals by the Ethics Committee/Regulatory Authority
  • Safety Review Committees/Independent Monitoring Boards
  • IP manufacturing
  • Vendors and their management

Duration: 50 minutes.

Speakers:

  • Vladimir Mukovozchik, Head of Project Management
  • Artūras Pažėra, Senior Project Manager
Vladimir Mukovozchik

Vladimir Mukovozchik

Head of Project Management

Other content that might interest you:

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Running a Clinical Trial in Ukraine

Running a Clinical Trial in Ukraine

Despite the fact that Ukraine is the largest country in Eastern Europe with a large population of treatment-naïve patients, well organized public health care sector and significant number of medical sites accredited for clinical trial conduction, country has utilized only 15% of its current potential for hosting clinical trials. During 2017, the European Medicine Agency (EMA) gave positive recommendations on 94 new drug applications and 49 of them were tested in clinical trials in Ukraine. During the same year, the US FDA approved 151 new drugs, and 28 of them were also studied in Ukraine.

read more
What You Need to Know about Running a Clinical Trial in Russia?

What You Need to Know about Running a Clinical Trial in Russia?

Russia is a very perspective country for international clinical trial conduction. The first international clinical trial was set up in Russia about 20 years ago only, and from than country kept a great potential for market development. In 2018 health authorities (HAs) approved 653 clinical trials (CT) in Russian Federation, less in overall numbers compared to the same indicator from 2016 – 898 approved CTs. However, this decrease was observed across all types of clinical trials except for international multicentre clinical trials (IMCT).

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information